AR106949A1 - Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales - Google Patents
Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumoralesInfo
- Publication number
- AR106949A1 AR106949A1 ARP160103720A ARP160103720A AR106949A1 AR 106949 A1 AR106949 A1 AR 106949A1 AR P160103720 A ARP160103720 A AR P160103720A AR P160103720 A ARP160103720 A AR P160103720A AR 106949 A1 AR106949 A1 AR 106949A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- syamg
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 7
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 abstract 1
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 abstract 1
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 abstract 1
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
También secuencias específicas de estos polipéptidos, métodos para su fabricación y métodos para usarlos, que incluyen métodos para el tratamiento de enfermedades, tales como el cáncer. Reivindicación 1: Un polipéptido que se fija específicamente a LRP5 o LRP6, caracterizado porque comprende: un primer dominio variable único de inmunoglobulina seleccionado del grupo de dominios variables únicos de inmunoglobina (i) a (iii) definidos por comprender las siguientes secuencias de CDR: (i): CDR1: TYTVG (= SEQ ID Nº 1), CDR2: AIRRRGSSTYYADSVKG (= SEQ ID Nº 2), CDR3: DTRTVALLQYRYDY (= SEQ ID Nº 3); (ii): CDR1: SYAMG (= SEQ ID Nº 4), CDR2: AIRRSGRRTYYADSVKG (= SEQ ID Nº 5), CDR3: ARRVRSSTRYNTGTWWWEY (= SEQ ID Nº 6); (iii): CDR1: RYTMG (= SEQ ID Nº 7), CDR2: AIVRSGGSTYYADSVKG (= SEQ ID Nº 8), CDR3: DRRGRGENYILLYSSGRYEY (= SEQ ID Nº 9), y un segundo dominio variable de inmunoglobulina seleccionado del grupo de dominios variables únicos de inmunoglobulina (iv) y (v) definidos por comprender las siguientes secuencias de CDR: (iv): CDR1: SYAMG (= SEQ ID Nº 10), CDR2: AISWSGGSTYYADSVKG (= SEQ ID Nº 11), CDR3: SPIPYGSLLRRRNNYDY (= SEQ ID Nº 12); (v): CDR1: SYAMG (= SEQ ID Nº 13), CDR2: AISWRSGSTYYADSVKG (= SEQ ID Nº 14), CDR3: DPRGYGVAYVSAYYEY (= SEQ ID Nº 15).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15197999 | 2015-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106949A1 true AR106949A1 (es) | 2018-03-07 |
Family
ID=54782606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103720A AR106949A1 (es) | 2015-12-04 | 2016-12-02 | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10597449B2 (es) |
| EP (2) | EP3383425B1 (es) |
| JP (2) | JP6728355B2 (es) |
| KR (1) | KR102802241B1 (es) |
| CN (1) | CN108289943B (es) |
| AR (1) | AR106949A1 (es) |
| AU (1) | AU2016363787B2 (es) |
| BR (1) | BR112018010537A2 (es) |
| CA (1) | CA3006235A1 (es) |
| CL (1) | CL2018001384A1 (es) |
| CO (1) | CO2018005680A2 (es) |
| CY (1) | CY1123454T1 (es) |
| DK (1) | DK3383425T3 (es) |
| EA (1) | EA201891331A1 (es) |
| ES (1) | ES2821099T3 (es) |
| HR (1) | HRP20201528T1 (es) |
| HU (1) | HUE051777T2 (es) |
| IL (1) | IL259119B (es) |
| LT (1) | LT3383425T (es) |
| MA (2) | MA54648A (es) |
| MX (1) | MX380414B (es) |
| MY (1) | MY200933A (es) |
| NZ (1) | NZ742037A (es) |
| PE (1) | PE20181515A1 (es) |
| PH (1) | PH12018501155B1 (es) |
| PL (1) | PL3383425T3 (es) |
| PT (1) | PT3383425T (es) |
| RS (1) | RS60823B1 (es) |
| SA (1) | SA518391728B1 (es) |
| SG (1) | SG11201804510PA (es) |
| SI (1) | SI3383425T1 (es) |
| TW (1) | TWI734719B (es) |
| UA (1) | UA122079C2 (es) |
| WO (1) | WO2017093478A1 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2968742T3 (es) | 2012-02-28 | 2024-05-13 | Novartis Ag | Selección de pacientes con cáncer para la administración de inhibidores de la señalización Wnt utilizando el estado mutacional de Rnf43 |
| KR102220275B1 (ko) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 및/또는 lag3 결합제 |
| AR106949A1 (es) | 2015-12-04 | 2018-03-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| KR102717656B1 (ko) * | 2017-05-31 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드 |
| EP3664830A4 (en) | 2017-08-07 | 2020-07-01 | The Regents of the University of California | RISK-FREE CELL THERAPEUTIC GENERATION PLATFORM |
| JP2021504492A (ja) | 2017-11-29 | 2021-02-15 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム | 癌治療のための組成物および方法 |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| DK3820906T3 (da) * | 2018-07-05 | 2025-12-15 | Surrozen Operating Inc | Multispecifikke wnt-surrogatmolekyler og anvendelser deraf |
| WO2020080941A1 (en) * | 2018-10-16 | 2020-04-23 | Umc Utrecht Holding B.V. | Anti- low-density lipoprotein receptor-related protein 5/6 antibodies |
| EP3947455A1 (en) | 2019-03-29 | 2022-02-09 | Boehringer Ingelheim International GmbH | Anticancer combination therapy |
| CN113646048A (zh) | 2019-03-29 | 2021-11-12 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| EP3966242A1 (en) | 2019-05-04 | 2022-03-16 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
| CN114402079A (zh) * | 2019-05-08 | 2022-04-26 | 印希彼有限公司 | Cd123靶向免疫疗法 |
| CN118909117A (zh) * | 2019-08-14 | 2024-11-08 | 安托拉诊疗公司 | 与lrp6蛋白结合的抗体及使用方法 |
| EP4013791A4 (en) * | 2019-08-14 | 2024-01-24 | Modmab Therapeutics Inc. | LRP5 PROTEIN-BINDING ANTIBODIES AND METHODS OF USE THEREOF |
| EP4034564A4 (en) | 2019-09-23 | 2023-12-13 | Twist Bioscience Corporation | VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES |
| CN112794914B (zh) * | 2019-11-14 | 2022-09-16 | 深圳华大生命科学研究院 | 一种基于噬菌体展示技术开发的alk纳米抗体及其应用 |
| WO2021163490A1 (en) * | 2020-02-14 | 2021-08-19 | University Of Washington | Targeted depletion of bacteria from mixed populations through programmable cell-cell adhesion |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| US20240391997A1 (en) * | 2021-07-16 | 2024-11-28 | Brightpath Biotherapeutics Co., Ltd. | Anti-tim-3 antigen antibody or antibody derivative, and use thereof |
| AU2023421423A1 (en) * | 2023-01-05 | 2025-07-17 | Harpoon Therapeutics, Inc. | Trop2 targeting trispecific protein for treatment of cancer |
| CN116375851B (zh) * | 2023-03-03 | 2024-03-22 | 中国农业科学院兰州兽医研究所 | 一种抗禽流感病毒np蛋白的纳米抗体及其制备方法与应用 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69330523D1 (de) | 1992-08-21 | 2001-09-06 | Vrije Universiteit Brussel Bru | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
| US6528054B1 (en) * | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| EP2275557A1 (en) | 2000-04-12 | 2011-01-19 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
| CA2484556A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003286002B2 (en) | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP5113523B2 (ja) | 2004-10-13 | 2013-01-09 | アブリンクス ナームローゼ フェンノートシャップ | アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| US7563619B2 (en) * | 2006-05-30 | 2009-07-21 | Van Andel Research Institute | Mammary stem cell marker |
| US8177435B2 (en) | 2006-06-08 | 2012-05-15 | Nsk Ltd. | Manufacturing method of a drawn cup needle roller bearing having seal ring |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| CN100428934C (zh) | 2006-09-07 | 2008-10-29 | 中国人民解放军第二军医大学 | 香豆素类化合物在制备诱导神经干细胞定向分化药物中的应用 |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US20080267949A1 (en) | 2006-12-05 | 2008-10-30 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| EP2567709B1 (en) | 2007-11-02 | 2017-12-27 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| WO2009109635A2 (en) | 2008-03-05 | 2009-09-11 | Ablynx Nv | Novel antigen binding dimer-complexes, methods of making and uses thereof |
| CN102089325A (zh) | 2008-04-17 | 2011-06-08 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽，以及包含其的化合物、构建体和多肽 |
| WO2010127216A2 (en) | 2009-05-01 | 2010-11-04 | Telcodia Technologies, Inc. | Automated determination of quasi-identifiers using program analysis |
| US8276148B2 (en) | 2009-12-04 | 2012-09-25 | International Business Machines Corporation | Continuous optimization of archive management scheduling by use of integrated content-resource analytic model |
| MX2012005345A (es) | 2009-12-23 | 2012-06-08 | Esbatech Alcon Biomed Res Unit | Metodo para disminuir inmunogenicidad. |
| CA2788993A1 (en) | 2010-02-05 | 2011-08-11 | Ablynx N.V. | Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same |
| UY33253A (es) | 2010-03-03 | 2011-09-30 | Boehringer Ingelheim Int | Polipéptidos de unión a a-beta |
| KR101899835B1 (ko) * | 2010-03-24 | 2018-09-19 | 제넨테크, 인크. | 항-ｌｒｐ６ 항체 |
| BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
| ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
| WO2012054565A1 (en) * | 2010-10-20 | 2012-04-26 | Genentech, Inc. | Methods and compositions for modulating the wnt pathway |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US8790650B2 (en) * | 2011-04-28 | 2014-07-29 | Vanderbilt University | Methods of using an antibody to inhibit WNT-mediated cardiac remodeling |
| DK2723769T4 (da) | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| EA027160B1 (ru) | 2011-08-17 | 2017-06-30 | Глаксо Груп Лимитед | Модифицированные белки и пептиды |
| JP2015502741A (ja) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| JP5949270B2 (ja) | 2012-07-24 | 2016-07-06 | 富士通株式会社 | オーディオ復号装置、オーディオ復号方法、オーディオ復号用コンピュータプログラム |
| WO2014029752A1 (en) * | 2012-08-22 | 2014-02-27 | Glaxo Group Limited | Anti lrp6 antibodies |
| AR106949A1 (es) | 2015-12-04 | 2018-03-07 | Boehringer Ingelheim Int | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales |
-
2016
- 2016-12-02 AR ARP160103720A patent/AR106949A1/es unknown
- 2016-12-02 UA UAA201807120A patent/UA122079C2/uk unknown
- 2016-12-02 WO PCT/EP2016/079575 patent/WO2017093478A1/en not_active Ceased
- 2016-12-02 TW TW105139826A patent/TWI734719B/zh active
- 2016-12-02 US US15/367,323 patent/US10597449B2/en active Active
- 2016-12-02 ES ES16808971T patent/ES2821099T3/es active Active
- 2016-12-02 MX MX2018006760A patent/MX380414B/es unknown
- 2016-12-02 PT PT168089712T patent/PT3383425T/pt unknown
- 2016-12-02 EP EP16808971.2A patent/EP3383425B1/en active Active
- 2016-12-02 HR HRP20201528TT patent/HRP20201528T1/hr unknown
- 2016-12-02 EA EA201891331A patent/EA201891331A1/ru unknown
- 2016-12-02 DK DK16808971.2T patent/DK3383425T3/da active
- 2016-12-02 MY MYPI2018000854A patent/MY200933A/en unknown
- 2016-12-02 HU HUE16808971A patent/HUE051777T2/hu unknown
- 2016-12-02 PE PE2018001063A patent/PE20181515A1/es unknown
- 2016-12-02 MA MA054648A patent/MA54648A/fr unknown
- 2016-12-02 KR KR1020187019053A patent/KR102802241B1/ko active Active
- 2016-12-02 AU AU2016363787A patent/AU2016363787B2/en active Active
- 2016-12-02 RS RS20201124A patent/RS60823B1/sr unknown
- 2016-12-02 NZ NZ742037A patent/NZ742037A/en unknown
- 2016-12-02 PL PL16808971T patent/PL3383425T3/pl unknown
- 2016-12-02 SI SI201630953T patent/SI3383425T1/sl unknown
- 2016-12-02 JP JP2018528327A patent/JP6728355B2/ja active Active
- 2016-12-02 EP EP20184267.1A patent/EP3797790A1/en not_active Withdrawn
- 2016-12-02 PH PH1/2018/501155A patent/PH12018501155B1/en unknown
- 2016-12-02 LT LTEP16808971.2T patent/LT3383425T/lt unknown
- 2016-12-02 BR BR112018010537-6A patent/BR112018010537A2/pt active Search and Examination
- 2016-12-02 SG SG11201804510PA patent/SG11201804510PA/en unknown
- 2016-12-02 MA MA43368A patent/MA43368B1/fr unknown
- 2016-12-02 CN CN201680071043.6A patent/CN108289943B/zh active Active
- 2016-12-02 CA CA3006235A patent/CA3006235A1/en active Pending
-
2018
- 2018-05-03 IL IL259119A patent/IL259119B/en unknown
- 2018-05-23 CL CL2018001384A patent/CL2018001384A1/es unknown
- 2018-05-29 CO CONC2018/0005680A patent/CO2018005680A2/es unknown
- 2018-06-04 SA SA518391728A patent/SA518391728B1/ar unknown
-
2020
- 2020-02-12 US US16/788,329 patent/US11952418B2/en active Active
- 2020-07-01 JP JP2020113792A patent/JP2020178701A/ja not_active Withdrawn
- 2020-10-12 CY CY20201100958T patent/CY1123454T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR106949A1 (es) | Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales | |
| PE20200610A1 (es) | Polipeptidos que antagonizan la senalizacion wnt en celulas tumorales | |
| MX2019008758A (es) | Anticuerpos anti-cd37 y usos de los mismos. | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| CO2017005738A2 (es) | Anticuerpos anti-pd-1 | |
| PE20190976A1 (es) | Anticuerpos de union a cd3 | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| AR101753A1 (es) | COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| MX381731B (es) | Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras. | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos |